ETF Growth Opportunities in Chinese Biotech

The video discusses a niche Chinese biotech ETF, comparing it with another healthcare ETF, CHIH. It highlights the emerging biotech sector in China, supported by government reforms and returning entrepreneurs. The impact of US-China trade relations on biotech is explored, noting that tariffs on medicines are unlikely. The video also covers trends in immunotherapy, with recent market challenges and future prospects. Finally, it discusses Hong Kong's new rules allowing biotech companies to list without revenue, positioning Hong Kong as a key player in biotech investments.

What are the characteristics of the ETF mentioned in the text?

How does the Chinese government support the biotech sector?

What challenges do biotech companies face in the context of US-China relations?

What is the significance of the new rule in Hong Kong for biotech companies?

Discuss the future prospects of immunotherapy based on the text.